
Patient Education and Support
An Lp(a) test does more than uncover a number—it provides an opportunity to educate your patients about their own personal CV risk. As awareness about elevated Lp(a) continues to increase, the following resources are available to help you and your patients make shared decisions about what to do next.
A conversation about elevated Lp(a) with your patients doesn’t have to be complicated
A Discussion Guide is available to help you answer frequently asked questions from patients about elevated Lp(a). Consider this tool for simplified language to help explain what elevated Lp(a) is and how it can impact their personal CV risk.
You can refer your patients to a site that can help explain Lp(a) in easy-to-understand terms
WhatIsLpa.com is a site for your patients to help them understand what elevated Lp(a) is, what it may mean for them and their families, and what steps they may take to manage their overall cardiovascular risk in consultation with their doctor.
Several online professional organizations support patients living with elevated Lp(a)
The Family Heart Foundation ↗ provides specific support for patients with elevated Lp(a), including education around its role in CV risk, information about what they and their families can do to mitigate its impact, and ways to connect with other people living with the same condition.
The Family Heart Foundation Lp(a) Support Group ↗ is a private Facebook group that provides timely, reliable, and relevant information for individuals living with elevated Lp(a) and their family members and caregivers.
Video Library
Elevated Lp(a) is a unique and genetically determined condition that can increase risk for ASCVD—and in patients younger than you might expect. Watch the videos to learn more.2-7
Lp(a) Testing Matters: A Real-World Perspective From Stephanie J Saucier, MD, FACC, RPVI
Lp(a) Testing Matters
Watch John’s Lp(a) Story
John’s Lp(a) Story
Watch Avery’s Lp(a) Story
Avery’s Lp(a) Story
FAQs
The role of Lp(a) testing in CV risk assessments has become a prominent topic of conversation amongst both cardiologists and professional organizations. Below are answers to some frequently asked questions about elevated Lp(a).
Stay informed with updates on elevated Lp(a).
ASCVD, atherosclerotic cardiovascular disease; CPT, Current Procedural Terminology; CV, cardiovascular; ICD-10, International Classification of Diseases, Tenth Revision; Lp(a), Lipoprotein (a).
References: 1. Koschinsky ML, Bajaj A, Boffa MB, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024;18(3):e308-e319. 2. Jawi MM, Frohlich J, Chan SY. Lipoprotein(a) the insurgent: a new insight into the structure, function, metabolism, pathogenicity, and medications affecting lipoprotein(a) molecule. J Lipids. 2020;2020:3491764. 3. Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69(6):692-711. 4. Reyes-Soffer G, Ginsburg H, Berglund L, et al. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(1):e48-e60. 5. Wilson DP, Jacobson TA, Jones PH, et al. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2019;13(3):374-392. 6. Rallidis LS, Pavlakis G, Foscolou A, et al. High levels of lipoprotein (a) and premature acute coronary syndrome. Atherosclerosis. 2018;269:29-34. 7. Tian X, Zhang N, Tse G, et al. Association between lipoprotein(a) and premature atherosclerotic cardiovascular disease: a systematic review and meta-analysis. Eur Heart J. 2024;4(3):oeae031. 8. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925-3946. 9. Writing Committee, Lloyd-Jones DM, Morris PB, et al. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;80(14):1366-1418. 10. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation. 2019;139(25):e1082-e1143. 11. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation. 2019;140(11):e596-e646. 12. Farzam K, Senthilkumaran S. Lipoprotein a. In: StatPearls. StatPearls Publishing; 2022. 13. Engler RJM, Brede E, Villines T, et al. Lipoprotein(a) elevation: a new diagnostic code with relevance to service members and veterans. Fed Pract. 2019;36(suppl 7):S19-S31. 14. Quest Diagnostics. Lipoprotein (a). Accessed January 25, 2025. https://testdirectory.questdiagnostics.com/test/testdetail/34604/lipoprotein-a?cc=MASTER 15. Kohn B, Ashraf AP, Wilson DP. Should lipoprotein(a) be measured in youth? J Pediatr. 2021 Jan;228:285-289. 16. Willeit P, Kiechl S, Kronenberg F, Mora S, Stroes ESG, et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a). J Am Coll Cardiol. 2014;64(9):851-860. 17. Madsen CM, Kamstrup PR, Langsted A, et al. Lipoprotein(a)-lowering by 50 mg/dL (105 nmol/L) may be needed to reduce cardiovascular disease 20% in secondary prevention. Arterioscler Thromb Vasc Biol. 2020;40:255-266. 18. Willeit P, Ridker P, Nestel P, et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet. 2018;392(10155):1311-1320. 19. Clarke R, Peden J, Hopewell J, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361:2518-2528.